Orion Capital Management LLC Raises Stock Position in Eli Lilly and Company (NYSE:LLY)

Orion Capital Management LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 18.7% in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,584 shares of the company’s stock after acquiring an additional 250 shares during the quarter. Orion Capital Management LLC’s holdings in Eli Lilly and Company were worth $923,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. JGP Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 0.9% during the 4th quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock valued at $1,074,000 after acquiring an additional 16 shares during the last quarter. Patton Albertson Miller Group LLC lifted its position in Eli Lilly and Company by 2.8% in the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after buying an additional 17 shares during the last quarter. Valley Wealth Managers Inc. lifted its position in Eli Lilly and Company by 1.3% in the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after buying an additional 17 shares during the last quarter. Sandy Cove Advisors LLC lifted its position in Eli Lilly and Company by 0.8% in the fourth quarter. Sandy Cove Advisors LLC now owns 2,241 shares of the company’s stock valued at $1,307,000 after buying an additional 17 shares during the last quarter. Finally, Lathrop Investment Management Corp lifted its position in Eli Lilly and Company by 1.2% in the third quarter. Lathrop Investment Management Corp now owns 1,476 shares of the company’s stock valued at $793,000 after buying an additional 18 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY stock remained flat at $781.10 during midday trading on Wednesday. 1,882,469 shares of the company’s stock were exchanged, compared to its average volume of 3,054,862. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The company has a market capitalization of $742.17 billion, a P/E ratio of 133.47, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34. The company’s fifty day moving average price is $761.41 and its 200-day moving average price is $669.21. Eli Lilly and Company has a 12 month low of $399.26 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.53 by $0.05. The business had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period last year, the firm posted $1.62 earnings per share. On average, research analysts anticipate that Eli Lilly and Company will post 12.51 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Wells Fargo & Company upped their target price on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research report on Tuesday, February 6th. JPMorgan Chase & Co. upped their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a research note on Wednesday, February 21st. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Finally, Citigroup boosted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and an average target price of $742.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.